[ad_1]
DUBLIN, February 13, 2019 / PRNewswire / –
The Dermatological Medicine Market by Treatment, Drug, Treatment Area, Prescribing Mode, Channel, End User, Geography – Global Market Size, Share, Development, Growth and Demand, 2013- 2023 "has been added to ResearchAndMarkets.com & # 39; s offer.
The dermatological drug market is expected to reach $ 34.5 billion by 2023, the increase in personal expenses, the large stockpile of dermatological drugs and the growing awareness of skin diseases are the main factors stimulating the demand for dermatological drugs worldwide.
On the basis of treatment, the dermatology market has been clbadified as topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, etc. Of these, organic products are expected to be the fastest growing category, with a compound annual growth rate of 9.1% over the forecast period.
On the basis of drugs, the dermatology drug market was mainly categorized as Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex and Eucrisa. Humira has registered the highest demand in the market, mainly in patients with psoriasis.
The main therapeutic areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars and skin cancer. The dermatology drug market recorded the highest revenues generated by psoriasis medications during the historical period. The category generated revenue from $ 14.2 billion on the market in 2017. The report also provides badysis of various therapeutic areas, based on the mode of prescription.
On the basis of prescription, the market was categorized as over-the-counter and prescription drugs, of which prescription drugs had a significant market share in 2017.
Based on distribution channels, the dermatology drug market has been categorized into direct, wholesale / retail and online channels. Of these, direct distribution channels are expected to generate the fastest market growth over the forecast period, with a CAGR of 8.5%. In addition, the main end-users covered by the study are hospitals, clinics, cosmetic centers and home users, where hospitals generate the highest income, namely $ 8.2 billionon the market in 2017. This can be attributed to the availability of improvements in health facilities and the increase in the number of patients in hospitals around the world.
Over the forecast period, the dermatology drug market is expected to experience the fastest growth in the ICCA, with a CAGR of 9.6%. This growth can be attributed to the increase in disposable income of the inhabitants of the region, resulting in a strong adoption of skincare products, including dermatological medications. In addition, the increase in the number of skin cancer cases in the region contributes to the high demand for these drugs.
In addition, several market players, as part of their business strategy, are exploring the untapped market of developing economies such as China and Indiawhich, in turn, supports the growth of the drug market for APAC Dermatology. For example, in October 2017, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical manufacturer, has received approval from the Drug Controller General of India to launch Otezla, a new clbad of oral psoriasis medications, after conducting clinical trials on patients with psoriasis for 16 weeks. The approval and launch of new drugs in developing countries is expected to boost the demand for dermatological drugs in ACPA over the forecast period.
Companies operating in the dermatology market are collaborating with other pharmaceutical companies to develop new and innovative products. For example, in November 2018Sanofi has collaborated with Denali Therapeutics Inc. (Denali), a biopharmaceutical company, to develop multiple molecules, DNL747 and DNL758, that can treat a variety of neurological and systemic inflammatory diseases. Under this agreement, Sanofi will pay $ 125 million in Denali to study the DNL747 leader molecule in multiple sclerosis, Alzheimer's disease and amyotrophic lateral sclerosis and DNL758 in systemic inflammatory diseases, such as rheumatoid arthritis and psoriasis.
In July 2018, Novartis AG has entered into a license agreement with Galapagos NV (Belgium) and MorphoSys AG (Germany), two biotechnology companies, for their compound MOR106. Under this agreement, Novartis has agreed to pay an upfront payment of $ 110.6 (95 million euros) Galapagos and MorphoSys to acquire the exclusive global development and commercialization rights of MOR106 for atopic dermatitis and all other potential indications.
Key topics covered:
Chapter 1. Context of the research
Chapter 2. Research Methodology
Chapter 3. Summary
Chapter 4. Introduction
4.1 Definition of market segments
4.1.1 By treatment
4.1.1.1 topical corticosteroids
4.1.1.2 Retinoids
4.1.1.3 Organic products
4.1.1.4 Calccineurin inhibitors
4.1.1.5 Antihistamines
4.1.1.6 Hormonal therapy
4.1.1.7 Other
4.1.2 By drugs
4.1.2.1 Humira
4.1.2.2 Remicade
4.1.2.3 Otezla
4.1.2.4 Stelara
4.1.2.5 Enbrel
4.1.2.6 Cosentyx
4.1.2.7 Neoral
4.1.2.8 Taltz
4.1.2.9 Cubicin
4.1.2.10 Canesten
4.1.2.11 Zyvox
4.1.2.12 Dupixent
4.1.2.13 Protopic
4.1.2.14 Valtrex
4.1.2.15 Eucrisa
4.1.2.16 Other
4.1.3 By prescription method
4.1.3.1 Prescription Drugs
4.1.3.2 Over-the-counter drugs
4.1.4 By therapeutic area
4.1.4.1 Psoriasis
4.1.4.2 Atopic dermatitis
4.1.4.3 Acne
4.1.4.4 Rosacea
4.1.4.5 Acne scars
4.1.4.6 Skin cancer
4.1.4.7 Other
4.1.5 By distribution channel
4.1.5.1 Direct
4.1.5.2 Wholesale / Retail
4.1.5.3 Online
4.1.6 By end user
4.1.6.1 Hospitals
4.1.6.2 Clinics
4.1.6.3 Cosmetic centers
4.1.6.4 At home
4.1.6.5 Other
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals
4.2.2 Drivers
4.2.2.1 Geriatric population on the rise
4.2.2.2 Increasing incidence of dermatological diseases
4.2.2.3 Increasing awareness of skin diseases
4.2.2.4 Increase in personal expenses
4.2.2.5 Solid Dermatological Drug Pipeline
4.2.2.6 Analysis of the impact of factors on market forecasts
4.2.3 Restraint
4.2.3.1 Expiry of the patent and development of a generic medicine
4.2.3.2 Side effects of certain clbades of therapeutic drugs
4.2.3.3 Analysis of the impact of restrictions on market forecasts
4.2.4 Opportunities
4.2.4.1 Huge potential in emerging markets
4.3 Analysis of Porter's Five Forces
Chapter 5. World Market Size and Forecasts
5.1 by treatment
5.2 by drug
5.3 By way of prescription
5.4 By therapeutic area
5.4.1 Pharmaceutical market for psoriasis dermatology, by way of prescription
5.4.2 Drug market for atopic dermatitis, by prescription method
5.4.3 Dermatological dermatology market for acne, by way of prescription
5.4.4 Dermatological medicines market for rosacea, by prescription method
5.4.5 Dermatological drugs market for acne scars, by prescription method
5.4.6 Dermatological medicines market for skin cancer, by prescription method
5.5 By distribution channel
5.6 per end user
5.7 by region
Chapter 6. Size and Forecasts of the North American Market
Chapter 7. Size and forecasts of the European market
Chapter 8. Market Size and Predictions APAC
Chapter 9. Market Size and LATAM Predictions
Chapter 10. Size and Forecasts of the MEA Market
Chapter 11. Competitive Landscape
11.1 Comparative badysis of the products of certain key players
11.2 Global strategic developments of key players
11.2.1 Product Launch / Approval
11.2.2 Partnerships and collaborations
11.2.3 Acquisitions
11.2.4 Development Results
11.2.5 Other developments
Chapter 12. Business Profiles
- Bausch Health Companies Inc.
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Allergan plc
- Merck & Co. Inc.
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and company
- Sanofi
- Nestl Skin Health S.A.
- GlaxoSmithKline plc
- Mylan N.V.
- LEO Pharma A / S
For more information on this report, visit https://www.researchandmarkets.com/research/kmdvcg/34_5_bn?w=5.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
Media contact:
Research and markets
Laura Wood, Main director
[email protected]
For E.S.T office hours, call + 1-917-300-0470
For toll-free calls to the United States and Canada + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
American fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
Source link
